YLB217
Anemia associated with chronic kidney disease and chemotherapy
NDA FiledUnder Regulatory Review
Key Facts
Indication
Anemia associated with chronic kidney disease and chemotherapy
Phase
NDA Filed
Status
Under Regulatory Review
Company
About YL Biologics
YL Biologics develops and commercializes high-quality biosimilar drugs to reduce healthcare costs and improve patient access to biologic therapies.
View full company profile